Perspective Therapeutics reported preliminary clinical data for Next-Generation Radiopharmaceuticals, demonstrating potential first-in-class therapeutic profiles for neuroendocrine tumors, refractory melanoma, and advanced solid tumors amidst a large solid tumor market opportunity.